Veeva Systems Unveils Falcon AI as Commercial Growth Gains Momentum

Veeva is expanding its AI strategy with Falcon, an agentic platform designed to manage complex, end-to-end life sciences workflows. The company says Falcon could reduce regulatory inquiry response times from about a month to less than a week, while Vault AI targets narrower tasks. Commercial growth remains strong and broad-based. Commercial subscriptions increased approximately 13% year over year in the second quarter, driven by products including Crossix, CRM, data offerings and content add-ons; more than 180 customers are live on Vault CRM. Veeva expects R&D growth to shift toward newer products such as EDC, eCOA and RTSM as mature offerings reach higher adoption. The company remains confident in its 2030 targets, while its Aspen CRM initiative is viewed as a longer-term opportunity beyond 2030.

Veeva is expanding its artificial intelligence roadmap while continuing to see broad-based growth across its life sciences software portfolio. Speaking at Citi’s Tech Conference, Van Wagener described Veeva as a vertical software provider focused predominantly on life sciences, which accounts for roughly 98% of its revenue. The company serves commercial, research and development, and quality operations through 10 suites and more than 50 products, spanning software and AI offerings.

Veeva had been deliberate rather than slow to adopt generative AI, citing the need for reliability in heavily regulated enterprise environments. “That reputation of having things that work as advertised is essential,” he said, adding that earlier AI models were not mature enough for life sciences applications.

Veeva accelerated its Vault AI roadmap over the past year, developing agents designed to help users perform work within its applications. Van Wagener contrasted those tools with Falcon, an agentic AI platform announced about three months ago that is intended to complete larger workflows from end to end, with human review still expected for critical processes.

As an example, he said Vault AI’s agentic call report helps pharmaceutical sales representatives prepare for meetings by synthesizing a physician’s history and prescribing patterns. The tool can save a representative 30 to 45 minutes of preparation time, he said. Falcon, in contrast, could handle a regulatory inquiry from a health authority by helping formulate a response strategy, conduct research, prepare documentation, secure approvals and submit the response. Van Wagener said Veeva believes that process could be reduced from about a month to less than a week. Early Falcon adopters span clinical, quality, regulatory, safety and commercial content applications, according to Van Wagener. The company expects Falcon eventually to be used across every product area, potentially with multiple agents serving individual areas. Veeva is currently approaching pricing for Vault AI on a consumption basis tied to tokens, while Falcon pricing is more likely to be based on business transactions, such as a reviewed document or a resolved and filed inquiry. Van Wagener said the company remains focused first on product maturity and reference customers before finalizing its commercial models.

Veeva does not require acquisitions to execute its Falcon strategy, but may pursue deals opportunistically.